NO20010509L - Endogene kontitutivt aktiverte G-proteinkoblede "foreldreløse" reseptorer - Google Patents

Endogene kontitutivt aktiverte G-proteinkoblede "foreldreløse" reseptorer

Info

Publication number
NO20010509L
NO20010509L NO20010509A NO20010509A NO20010509L NO 20010509 L NO20010509 L NO 20010509L NO 20010509 A NO20010509 A NO 20010509A NO 20010509 A NO20010509 A NO 20010509A NO 20010509 L NO20010509 L NO 20010509L
Authority
NO
Norway
Prior art keywords
endogenous
protein
orphan
receptors
coupled
Prior art date
Application number
NO20010509A
Other languages
English (en)
Norwegian (no)
Other versions
NO20010509D0 (no
Inventor
Dominic P Behan
Derek T Chalmers
Chen Liaw
I-Lin Lin
Kevin Lowitz
Ruoping Chen
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of NO20010509D0 publication Critical patent/NO20010509D0/no
Publication of NO20010509L publication Critical patent/NO20010509L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30Oxygen or sulfur atoms
    • C07D233/42Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cosmetics (AREA)
NO20010509A 1998-07-31 2001-01-30 Endogene kontitutivt aktiverte G-proteinkoblede "foreldreløse" reseptorer NO20010509L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9487998P 1998-07-31 1998-07-31
US10630098P 1998-10-30 1998-10-30
US11090698P 1998-12-04 1998-12-04
US12185199P 1999-02-26 1999-02-26
PCT/US1999/017425 WO2000006597A2 (en) 1998-07-31 1999-07-30 Endogenous constitutively activated g protein-coupled orphan receptors

Publications (2)

Publication Number Publication Date
NO20010509D0 NO20010509D0 (no) 2001-01-30
NO20010509L true NO20010509L (no) 2001-03-19

Family

ID=27492754

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010509A NO20010509L (no) 1998-07-31 2001-01-30 Endogene kontitutivt aktiverte G-proteinkoblede "foreldreløse" reseptorer

Country Status (13)

Country Link
EP (1) EP1095275B1 (https=)
JP (1) JP2002521681A (https=)
CN (1) CN1231762C (https=)
AT (1) ATE432472T1 (https=)
AU (1) AU751080B2 (https=)
CA (1) CA2338543C (https=)
DE (1) DE69940923D1 (https=)
DK (1) DK1095275T3 (https=)
IL (1) IL140858A0 (https=)
MX (1) MXPA01001176A (https=)
NO (1) NO20010509L (https=)
NZ (1) NZ509429A (https=)
WO (1) WO2000006597A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
CN1420929A (zh) * 2000-04-07 2003-05-28 阿瑞那制药公司 非内源性组成型活化的已知g蛋白偶联受体
AU2003218234A1 (en) * 2002-03-15 2003-09-29 Arena Pharmaceuticals, Inc. Methods of expressing non-endogenous g protein coupled receptors in cells
WO2003081256A2 (en) * 2002-03-22 2003-10-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human g protein-coupled orphan receptor 21 (gpr21)
AU2003266238A1 (en) * 2002-08-05 2004-02-25 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with ovarian cancer g-protein coupled receptor 1 (ogr-1)
WO2004056869A1 (en) * 2002-12-20 2004-07-08 7Tm Pharma A/S Ghrelin receptor inverse agonist for regulation of feeding behaviours
WO2005095990A1 (en) * 2004-03-25 2005-10-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 52 (gpr52)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11507518A (ja) * 1995-06-07 1999-07-06 プレーシス ファーマスーティカルズ インコーポレイテッド G蛋白質とカップルしたレセプターのアゴニスト及びアンタゴニストの機能的バイオアッセイ
AU7115896A (en) * 1995-09-20 1997-04-09 Molecular Geriatrics Corporation Yeast receptor and g-protein fusion protein
DK0965041T3 (da) * 1997-04-14 2009-05-25 Arena Pharm Inc Fremgangsmåde til identifikation af modulatorer af celleoverflade-membranreceptorer, som kan anvendes til behandling af sygdomme

Also Published As

Publication number Publication date
EP1095275A2 (en) 2001-05-02
DK1095275T3 (da) 2009-09-28
EP1095275B1 (en) 2009-05-27
JP2002521681A (ja) 2002-07-16
AU5545999A (en) 2000-02-21
CN1231762C (zh) 2005-12-14
CA2338543C (en) 2009-12-29
WO2000006597A3 (en) 2000-05-18
CN1323396A (zh) 2001-11-21
ATE432472T1 (de) 2009-06-15
CA2338543A1 (en) 2000-02-10
WO2000006597A9 (en) 2000-07-13
MXPA01001176A (es) 2005-07-25
AU751080B2 (en) 2002-08-08
NZ509429A (en) 2002-06-28
NO20010509D0 (no) 2001-01-30
WO2000006597A2 (en) 2000-02-10
IL140858A0 (en) 2002-02-10
DE69940923D1 (de) 2009-07-09

Similar Documents

Publication Publication Date Title
EA200100773A1 (ru) Замещенные 1-гетероциклические диариламины
TR199801679T2 (xx) Osteoporoz i�in birle�tirme terapisi.
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
DK1199069T3 (da) Anvendelse af en estrogenagonist/-antagonist til forbedring eller bibeholdelse af urogenital sundhed
DK1135153T3 (da) Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser
ITMI991964A0 (it) Derivati benzimidazolonici aventi affinita' mista per i recettori di s erotonina e dopamina
CY1107821T1 (el) Πολυπεπτιδιο παραγοντα viii με ενεργοτητα παραγοντα viii:c
ES2162231T3 (es) Nuevos derivados de n-(arilsulfonil)aminoacidos que tienen afinidad con los receptores de bradicinina.
LTPA2014028I1 (lt) Pakeistieji 3-cianochinolinai kaip proteintirozinkinazės inhibitoriai
NO20003221L (no) Ny G-proteinkoblet reseptor
ES2162676T3 (es) Derivados de fenileno sustituidos en meta y su uso como antagonistas o inhibidores de integrina alfav,beta3.
BRPI0417684A (pt) composto, composição farmacêutica, e, uso de um composto
TR200101398T2 (tr) Pirolidin türevleri-CCR-3 reseptörü antagonistleri.
AR020442A1 (es) Agonistas de 5ht2serotonergicos para el tratamiento de glaucoma
BR0007864A (pt) Composto, e, uso de um composto
EA200300593A1 (ru) Соединения пиперазинилпиразинов в качестве агонистов или антагонистов серотонин 5-ht2 рецептора
DK0736525T3 (da) Benzonitriler som 5-HT-agonister og -antagonister
EA199900362A1 (ru) Новые соединения, полезные для использования в качестве нейрозащитных средств
ATE322503T1 (de) Gefrierschutzprotein
FI962969L (fi) Indolijohdannaisia 5-HT1:n agonisteina
EA200001039A1 (ru) Кальцилитические соединения
BR0113321A (pt) Combinação farmacêutica de antagonistas de angiotensina ii e inibidores da enzima conversora de angiotensina i
CO5460266A1 (es) Novedosos analogos de la somatostatina
NO20010509L (no) Endogene kontitutivt aktiverte G-proteinkoblede "foreldreløse" reseptorer
BR0108454A (pt) Métodos para identificação e uso de antagonistas de receptor de adenosina a(2b) papa mediar a proliferação celular em mamìferos